Cancer Alternative Therapies
Methodology & AI Transparency ⓘ
Cancer Alternative Therapies Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are complementary and alternative therapies for cancer care? You have many choices to make about your cancer treatment.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C43.5 for Cancer Alternative Therapies clinical workups.
- 3 Typical cash cost range: Differential triage of Cancer Alternative Therapies (C43.5) utilizes radiation) paired with in Cancer Alternative Therapies (C43.5: proactive supportive symptom).
- 4 Top reported side effects / signs: Longitudinal Cancer Alternative Therapies monitoring tracks Complete Blood Count in Cancer Alternative Therapies (C43.5: (ANC, Hemoglobin, Platelets)) toward Safe hematologic reserve (C43.5).
Ask our AI Specialists anything about Cancer Alternative Therapies
What Is Cancer Alternative Therapies?
What are complementary and alternative therapies for cancer care? You have many choices to make about your cancer treatment. One choice you might consider is using complementary and alternative medicine (CAM). CAM is the term for medical products and therapies that are not part of standard medical care. CAM for cancer treatment involves caring for your mind, body, and spirit. Some methods focus on your breathing or body movements to help you relax. Other CAM therapies may use special foods, supplements , or diets. Examples of CAM therapies include acupuncture , chiropractic , and herbal medicines .
Pathophysiology, Underlying Causes & Clinical Presentation
In Cancer Alternative Therapies (C43.5), physiological disruption stems from immune-checkpoint evasion [Cancer Alternative Therapies C43.5], Cross-referenced with NIH MeSH (Complementary Therapies, Neoplasms), informing Cancer, Oncology & Supportive Care protocols that track Comprehensive Metabolic & in Cancer Alternative Therapies (C43.5: Organ Function Panel) (Preserved renal/hepatic clearance (C43.5)).
Common Symptoms & Clinical Signs
- • Help cope with the side effects of cancer treatments
- • Ease worries about cancer treatment and related stress
- • Presentation of Cancer Alternative Therapies (C43.5): unintended weight loss [Cancer Alternative Therapies C43.5]
- • Secondary Cancer Alternative Therapies clinical sign: unexplained bleeding, chronic in Cancer Alternative Therapies (C43.5: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cancer Alternative Therapies Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C43.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Cancer Alternative Therapies (C43.5: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C43.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Cancer Alternative Therapies (C43.5: Organ Function Panel) | Preserved renal/hepatic clearance (C43.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Cancer Alternative Therapies (C43.5: Genomic Staging) | Guideline-concordant surveillance (C43.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cancer Alternative Therapies
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Waskyra (Etuvetidigene Autotemcel) Waskyra • RxCUI RXN-B876680100 | FDA Prescription Therapeutic Agent | 77% | $1.8200 | $ 139.54 /mo |
| Amikacin Arikayce • RxCUI 2059184 | Aminoglycoside Antibacterial | 74% | $2.7228 | $ 118.77 /mo |
| Aztreonam and Avibactam Emblaveo • RxCUI 2705355 | Monobactam Antibacterial | 77% | $3.3900 | $ 145.80 /mo |
| Dipyridamole Persantine • RxCUI 309953 | Platelet Aggregation Inhibitor | 91% | $0.2358 | $ 6.38 /mo |
| Caplyta (Lumateperone) Caplyta • RxCUI RXN-B72060121 | Atypical Antipsychotic | 85% | $54.6223 | $ 640.00 /mo |
| Nefazodone Hydrochloride Serzone • RxCUI 1098649 | Serotonin Reuptake Inhibitor | 90% | $1.1657 | $ 37.38 /mo |
| Felbamate Felbatol • RxCUI 198358 | Anti-epileptic Agent | 83% | $14.6851 | $ 26.22 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cancer Alternative Therapies)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer:: What a 1,052-Participant Study Found While further stratification by metastasis timing suggested no clear survival benefit in the double low synchronous subgroup, wide CIs indicate substantial uncertainty. World journal of urology • 2026-08-19 • Phase III Randomized Trial | N = 1,052 | 96/100 | PMID 42616151 ↗ |
| New Insights on Age-related real-world benefits and safety of Darolutamide Plus: What a 1,086-Participant Study Found In the 219 patients aged ≥75 yr in ARASENS, darolutamide demonstrated improved efficacy versus placebo and favorable safety, consistent with the findings in patients aged <75 yr. European urology oncology • 2026-06-15 • Phase III Randomized Trial | N = 1,086 | 96/100 | PMID 41193271 ↗ |
| New Insights on Veliparib concomitant with first-line chemotherapy and as maintenance therapy in: What a 1,140-Participant Study Found No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed. European journal of cancer (Oxford, England : 1990) • 2025-07-25 • Phase III Randomized Trial | N = 1,140 | 96/100 | PMID 40561681 ↗ |
| New Insights on Development and validation of a multivariable prognostic model in de novo: What a 1,058-Participant Study Found A prognostic model for men with de novo mCSPC was developed and validated in an independent testing set. Prostate cancer and prostatic diseases • 2023-03-15 • Phase III Randomized Trial | N = 1,058 | 96/100 | PMID 35790787 ↗ |
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
Cancer Alternative Therapies Patient Community & “People Like Me” Threads
Filter Cancer Alternative Therapies community threads and patient logs by age, biological sex, dosage, and treatment duration.